Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 5/20 | 0.42 |
| ▸ | CTSL | P07711 | 5/20 | 0.37 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.36 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13624398 | 0.81 | CTSL (0.39) | CTSKCTSLTAS1R3TAS1R1MEN1 | |
| SCHEMBL4364936 | 0.79 | TAS1R3 (0.38) | CTSKCTSLTAS1R3TAS1R1MEN1 | |
| SCHEMBL4364927 | 0.79 | TAS1R3 (0.38) | CTSKCTSLTAS1R3TAS1R1MEN1 | |
| SCHEMBL13624321 | 0.76 | CTSL (0.57) | CTSKCTSLTAS1R3TAS1R1MEN1 | |
| SCHEMBL13624401 | 0.76 | CTSK (0.51) | CTSKCTSL | |
| SCHEMBL13624358 | 0.76 | CTSL (0.52) | CTSKCTSLTAS1R3TAS1R1MEN1 | |
| SCHEMBL13624452 | 0.74 | CTSK (0.45) | CTSKCTSL | |
| SCHEMBL13624328 | 0.74 | CTSL (0.58) | CTSKCTSLMEN1KMT2A | |
| SCHEMBL4367873 | 0.74 | MAPT (0.35) | CTSKCTSLTAS1R3TAS1R1 | |
| SCHEMBL13624454 | 0.74 | CTSK (0.45) | CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSK 15/4885CTSL 24/4885PSMB5 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.